Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using diffusion MRI to relate hippocampal subfield microstructure to delayed verbal memory in cognitively intact individuals at genetic risk for developing Alzheimer's disease.

Experimental gerontology·2026
Same author

AI-Driven Prediction of Possible Mild Cognitive Impairment Using the Oculo-Cognitive Addition Test (OCAT).

Brain sciences·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Free-water imaging of the nucleus basalis of Meynert in apolipoprotein E4 carriers.

Frontiers in aging neuroscience·2025
Same author

PLASMA-CYCLEGAN: PLASMA BIOMARKER-GUIDED MRI TO PET CROSS-MODALITY TRANSLATION USING CONDITIONAL CYCLEGAN.

Proceedings. IEEE International Symposium on Biomedical Imaging·2025
Same author

Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

γ-radiation reduces phosphorylated-tau in rhesus macaque brains: potential implications for Alzheimer's disease and other tauopathies.

Alzheimer's research & therapy·2026
Same journal

The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.

Alzheimer's research & therapy·2026
Same journal

Smoking cessation duration and risk of Alzheimer's disease: a nationwide cohort study in Korea.

Alzheimer's research & therapy·2026
Same journal

Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA).

Alzheimer's research & therapy·2026
Same journal

Structural and molecular determinants of medial temporal lobe network vulnerability in aging and Alzheimer's disease.

Alzheimer's research & therapy·2026
Same journal

Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.

Alzheimer's research & therapy·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications.

Richard J Caselli1

  • 1Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. caselli.richard@mayo.edu.

Alzheimer'S Research & Therapy
|June 15, 2012
PubMed
Summary
This summary is machine-generated.

Apolipoprotein E (APOE) e4 carriers show faster Alzheimer's disease progression and increased amyloid burden. This impacts clinical trial design but not current clinical practice for disease modification.

More Related Videos

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Related Experiment Videos

Last Updated: May 21, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Alzheimer's disease (AD) research is increasingly focused on modifying disease course and early intervention.
  • The apolipoprotein E (APOE) genotype is a significant genetic risk factor for AD.
  • Understanding APOE's influence is crucial for designing effective AD studies and treatments.

Purpose of the Study:

  • To examine the confounding impact of apolipoprotein E (APOE) genotype on Alzheimer's disease.
  • To evaluate APOE's effect on preclinical and mild cognitive impairment (MCI) stages.
  • To assess APOE's influence on therapeutic outcomes and clinical practice.

Main Methods:

  • Review of existing literature on APOE genotype and Alzheimer's disease.
  • Analysis of cognitive decline rates in APOE e4 carriers.
  • Examination of cerebrovascular amyloid burden and adverse events in relation to APOE genotype.

Main Results:

  • APOE e4 carriers exhibit accelerated cognitive decline in preclinical and MCI stages.
  • Increased cerebrovascular amyloid burden is observed in APOE e4 carriers.
  • A gene-dose-related increase in meningoencephalitis and microhemorrhages with immunomodulatory therapy is linked to APOE genotype.

Conclusions:

  • APOE genotype significantly influences Alzheimer's disease progression and risk.
  • The APOE e4 allele necessitates careful consideration in AD clinical trial design.
  • Current clinical practice has not yet fully adapted to the implications of APOE genotype in AD management.